Since 2011, Mika has been an Operational Partner with Gilde Healthcare Partners, a life-science focused venture fund with $1.5B under management and a currently investing out of Gilde V, a $460M fund. In her most recent operating role, Mika was Vice President, Commercialization at nVision Medical Corporation, an early clinical-stage company focused on early detection of ovarian cancer acquired by Boston Scientific for $275M. Previously, Mika was Vice President, Commercial Development at Auxogyn, a company focused on reproductive health. Progyny, Inc acquired the company in 2015. She currently serves as Independent Director for SI Bone (Nasdaq: SIBN), Accuray (Nasdaq: ARAY), and HOYA (Tokyo Stock Exchange Prime: 7741). Earlier in her career, Mika was Vice President, International Sales Operations and Marketing at ev3 Inc., where she held P&L responsibilities for the emerging markets. Mika has an MBA from Harvard Graduate School of Business Administration and a BA in Economics from Yale University.

Not yet provided

Not yet provided

Not yet provided